Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis (COVIDOSE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04331795
Recruitment Status : Recruiting
First Posted : April 2, 2020
Last Update Posted : May 1, 2020
Sponsor:
Information provided by (Responsible Party):
University of Chicago

Brief Summary:

Coronavirus disease-2019 (COVID-19) has a quoted inpatient mortality as high as 25%. This high mortality may be driven by hyperinflammation resembling cytokine release syndrome (CRS), offering the hope that therapies targeting the interleukin-6 (IL-6) axis therapies commonly used to treat CRS can be used to reduce COVID-19 mortality. Retrospective analysis of severe to critical COVID-19 patients receiving tocilizumab demonstrated that the majority of patients had rapid resolution (i.e., within 24-72 hours following administration) of both clinical and biochemical signs (fever and CRP, respectively) of hyperinflammation with only a single tocilizumab dose.

Hypotheses:

  1. Tocilizumab is effective in decreasing signs, symptoms, and laboratory evidence of COVID-19 pneumonitis in hospitalized, non-critically ill patients with clinical risk factors for clinical decompensation, intensive care utilization, and death.
  2. Low-dose tocilizumab is effective in decreasing signs, symptoms, and laboratory evidence of COVID-19 pneumonitis in hospitalized, non-critically ill patients with and without clinical risk factors for clinical decompensation, intensive care utilization, and death.

Objectives:

  1. To establish proof of concept that tocilizumab is effective in decreasing signs, symptoms, and laboratory evidence of COVID-19 pneumonitis in hospitalized, non-critically ill patients with clinical risk factors for clinical decompensation, intensive care utilization, and death, as determined by the clinical outcome of resolution of fever and the biochemical outcome measures of time to CRP normalization for the individual patient and the rate of patients whose CRP normalize.
  2. To establish proof of concept that low-dose tocilizumab is effective in decreasing signs, symptoms, and laboratory evidence of COVID-19 pneumonitis in hospitalized, non-critically ill patients without clinical risk factors for clinical decompensation, intensive care utilization, and death, as determined by the clinical outcome of resolution of fever and the biochemical outcome measures of time to CRP normalization for the individual patient and the rate of patients whose CRP normalize.

Condition or disease Intervention/treatment Phase
COVID-19 Drug: Tocilizumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Early Institution of Tocilizumab Titration in Non-Critical Hospitalized COVID-19 Pneumonitis
Actual Study Start Date : April 4, 2020
Estimated Primary Completion Date : July 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Pneumonia
Drug Information available for: Tocilizumab

Arm Intervention/treatment
Experimental: Group A
Hospitalized, non-critically ill patients with COVID-19 pneumonitis with risk factors for decompensation
Drug: Tocilizumab

Group A: Tocilizumab (beginning dose 200mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.

Second dose is provisioned if:

  1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND
  2. CRP decrease is < 25% at 24 hours following tocilizumab administration and CRP > 40mg/L

Experimental: Group B
Hospitalized, non-critically ill patients with COVID-19 pneumonitis without risk factors for decompensation
Drug: Tocilizumab

Group B: Low-dose tocilizumab (beginning dose 80mg) Single dose is provisioned, patient is eligible to receive up to two doses, with re-evaluation of clinical and biochemical responses performed every 24 hours.

Second dose is provisioned if:

  1. Increasing supplemental oxygen requirement or Tmax higher than baseline in the 24h following initial tocilizumab administration AND
  2. CRP decrease is < 25% at 24 hours following tocilizumab administration and CRP > 40mg/L




Primary Outcome Measures :
  1. Clinical response [ Time Frame: Assessed for the 24 hour period after tocilizumab administration ]
    Tmax Response: Resolution of fever (from Tmax > 38C in 24H period to Tmax < 38C in following 24H period, with Tmax measured by commonly accepted clinical methods [forehead, tympanic, oral, axillary, rectal]). Maximum temperature within 24-hour period of time (0:00-23:59) on the day prior to, day of, and every 24 hours after tocilizumab administration. The primary endpoint is absence of Tmax greater than or equal to 38ºC in the 24-hour period following tocilizumab administration.

  2. Biochemical response [ Time Frame: Assessed every 24 hours during patient's hospitalization, up to 4 weeks after tocilizumab administration ]

    CRP normalization rate: Calculated as the ratio of the number of patients who achieve normal CRP value following tocilizumab administration and total number of patients who receive tocilizumab.

    Time to CRP normalization: Calculated as the number of hours between tocilizumab administration and first normal CRP value.



Secondary Outcome Measures :
  1. Overall survival [ Time Frame: 28 days ]
    28-Day Overall Survival is defined as the status of the patient at the end of 28 days, beginning from the time of the first dose of tocilizumab.

  2. Survival to hospital discharge [ Time Frame: Hospitalization, up to 4 weeks after tocilizumab administration ]
    This will be defined as the percentage of patients who are discharged in stable condition compared to the percentage of patients who die in the hospital. Patients who are discharged to hospice will be excluded from this calculation.

  3. Progression of COVID-19 pneumonitis [ Time Frame: Hospitalization, up to 4 weeks after tocilizumab administration ]
    This will be a binary outcome defined by worsening COVID-19 pneumonitis resulting in transition from clinical Group A or Group B COVID-19 pneumonitis to critical COVID-19 pneumonitis during the course of the patient's COVID-19 infection. This diagnosis will be determined by treating physicians on the basis of worsening pulmonary infiltrates on chest imaging as well as clinical deterioration marked by persistent fever, rising supplemental oxygen requirement, declining PaO2/FiO2 ratio, and the need for intensive care such as mechanical ventilation or vasopressor/inotrope medication(s).

  4. Rate of non-elective mechanical ventilation [ Time Frame: Hospitalization, up to 4 weeks after tocilizumab administration ]
    This will be a binary outcome defined as worsening COVID-19 disease resulting in the use of non-invasive (BiPap, heated high-flow nasal cannula) or invasive positive pressure ventilation during the course of the patient's COVID-19 infection. For patients admitted to the hospital using non-invasive mechanical ventilation, the utilization of mechanical ventilation will count toward this metric, as well. Calculated as the ratio of the number of patients who require non-invasive or invasive positive pressure ventilation during hospitalization and total number of patients who receive tocilizumab.

  5. Duration of mechanical ventilation [ Time Frame: Hospitalization, up to 4 weeks after tocilizumab administration ]
    This will be a continuous outcome defined by the amount of time between initiation and cessation of mechanical ventilation (invasive and non-invasive).

  6. Time to mechanical ventilation [ Time Frame: Assessed over hospitalization, up to 4 weeks after tocilizumab administration ]
    This will be a continuous outcome defined by the amount of time between tocilizumab dose administration and the initiation of mechanical ventilation. This will be treated as a time-to-event with possible censoring.

  7. Rate of vasopressor/inotrope utilization [ Time Frame: Hospitalization, up to 4 weeks after tocilizumab administration ]
    This will be a binary outcome defined as utilization of any vasopressor or inotropic medication during the course of the patient's COVID-19 infection. Calculated as the ratio of the number of patients who require vasopressor or inotrope medication during hospitalization and total number of patients who receive tocilizumab.

  8. Duration of vasopressor/inotrope utilization [ Time Frame: Hospitalization, up to 4 weeks after tocilizumab administration ]
    This will be a continuous outcome defined by the amount of time between initiation of first and cessation of last vasopressor or inotrope medication(s).

  9. Time to vasopressor or inotropic utilization [ Time Frame: Assessed over hospitalization, up to 4 weeks after tocilizumab administration ]
    This will be a continuous outcome defined by the amount of time between first tocilizumab dose administration and the initiation of vasopressor or inotropic medication(s). This will be treated as a time-to-event with possible censoring.

  10. Number of ICU days [ Time Frame: Hospitalization, up to 4 weeks after tocilizumab administration ]
    Number of ICU days is defined as the time period when a patient is admitted to the ICU (defined as the timestamp on the first vital signs collected in an ICU) until they are transferred from the ICU to a non-ICU setting such as a general acute care bed (defined as the timestamp on the first vital signs collected outside an ICU, excepting any "off the floor" vital signs charted from operating rooms or procedure or imaging suites). Death in the ICU will be a competing risk.

  11. Duration of Increased Supplemental Oxygen Requirement from Baseline [ Time Frame: Assessed over hospitalization, up to 4 weeks after tocilizumab administration ]
    Duration of increased supplemental oxygen requirement from baseline is defined as the time period (number of days) during which the participant requires supplemental oxygen in excess of his/her baseline supplemental oxygen requirement. The supplemental oxygen requirement is defined as the highest liters-per-minute flow of supplemental oxygen required by the patient each day over the course of the hospitalization.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Adults ≥ 18 years of age
  • Approval from the patient's primary service
  • Admitted as an inpatient to University of Chicago Medicine
  • Fever, documented in electronic medical record and defined as: T ≥ 38*C by any conventional clinical method (forehead, tympanic, oral, axillary, rectal)
  • Positive test for active SARS-CoV-2 infection
  • Radiographic evidence of infiltrates on chest radiograph (CXR) or computed tomography (CT)
  • Ability to provide written informed consent on the part of the subject or, in the absence of decisional capacity of the subject, an appropriate surrogate (e.g. a legally authorized representative).

Exclusion Criteria:

  • Concurrent use of invasive mechanical ventilation (patients receiving non-invasive mechanical ventilation [CPAP, BiPap, HHFNC] are eligible)
  • Concurrent use of vasopressor or inotropic medications
  • Previous receipt of tocilizumab or another anti-IL6R or IL-6 inhibitor.
  • Known history of hypersensitivity to tocilizumab.
  • Patients who are actively being considered for a study of an antiviral agent that would potentially exclude concurrent enrollment on this study.
  • Patients actively receiving an investigational antiviral agent in the context of a clinical research study.
  • Diagnosis of end-stage liver disease or listed for liver transplant.
  • Elevation of AST or ALT in excess of 5 times the upper limit of normal.
  • Neutropenia (Absolute neutrophil count < 500/uL).
  • Thrombocytopenia (Platelets < 50,000/uL).
  • On active therapy with a biologic immunosuppressive agent, which include the following biologics and any biosimilar versions thereof:
  • Alemtuzumab
  • Blinatumomab
  • Brentuximab
  • Daratumumab
  • Elotuzumab
  • Ibritumomab
  • Obinutuzumab
  • Ofatumumab
  • Ocrelizumab
  • Rituximab
  • Inotuzumab
  • Gemtuzumab
  • Tositumumab
  • Moxetumomab
  • Polatuzumab
  • Abatacept
  • Adalimumab
  • Belimumab
  • Certolizumab
  • Eculizumab
  • Etanercept
  • Golimumab
  • Infliximab
  • Ixekizumab
  • Rituximab
  • Sarilumab
  • Secukinumab
  • Tocilizumab
  • Ustekinumab
  • On active therapy with a JAK2-targeted agent, which include the following:
  • Tofacitinib
  • Baricitinib
  • Upadacitinib
  • Ruxolitinib
  • History of bone marrow transplantation or solid organ transplant.
  • Known history of Hepatitis B or Hepatitis C.
  • Known history of mycobacterium tuberculosis infection at risk for reactivation.
  • Known history of gastrointestinal perforation or active diverticulitis.
  • Multi-organ failure as determined by primary treating team
  • Any other documented serious, active infection besides COVID-19.
  • Pregnant patients
  • Patients who are unable to discontinue scheduled antipyretic medications, either as monotherapy (e.g., acetaminophen or ibuprofen [aspirin is acceptable]) or as part of combination therapy (e.g., hydrocodone/acetaminophen, aspirin/acetaminophen/caffeine [Excedrin®])
  • CRP < 40 mg/L (or ug/mL)

Patients will be assigned to Group A if:

● C-reactive protein (CRP) ≥ 75 ug/mL

AND

Any one of the following criteria are met:

  • Previous ICU admission
  • Previous non-elective intubation
  • Admission for heart failure exacerbation within the past 12 months
  • History of percutaneous coronary intervention (PCI)
  • History of coronary artery bypass graft (CABG) surgery
  • Diagnosis of pulmonary hypertension
  • Baseline requirement for supplemental O2
  • Diagnosis of interstitial lung disease (ILD)
  • Admission for chronic obstructive pulmonary disease (COPD) exacerbation within the past 12 months
  • Asthma with use of daily inhaled corticosteroid
  • History of pneumonectomy or lobectomy
  • History of radiation therapy to the lung
  • History of HIV
  • Cancer of any stage and receiving active treatment (excluding hormonal therapy)
  • Any history of diagnosed immunodeficiency
  • End-stage renal disease (ESRD) requiring peritoneal or hemodialysis
  • History of cerebrovascular accident with residual, patient-reported neurologic deficit
  • BMI >30 kg/m2
  • Supplemental O2 requirement > 6L in the 24 hours prior to enrollment and tocilizumab administration

All other eligible patients assigned to Group B


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04331795


Contacts
Layout table for location contacts
Contact: Pankti Reid, MD, MPH 7737021220 pankti.reid@uchospitals.edu

Locations
Layout table for location information
United States, Illinois
University of Chicago Medicine Recruiting
Chicago, Illinois, United States, 60637
Contact: Pankti Reid, MD, MPH         
Sponsors and Collaborators
University of Chicago
Investigators
Layout table for investigator information
Principal Investigator: Pankti Reid, MD, MPH University of Chicago, Department of Medicine, Section of Rheumatology
Layout table for additonal information
Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT04331795    
Other Study ID Numbers: IRB20-0515
First Posted: April 2, 2020    Key Record Dates
Last Update Posted: May 1, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Lung Diseases
Respiratory Tract Diseases
Respiratory Tract Infections